Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens

BACKGROUND: Hepatitis C virus (HCV) is a risk factor for chronic kidney disease (CKD) and end-stage renal disease (ESRD). Direct-acting antiviral agents (DAAs) have improved HCV management in CKD patients, however real-world clinical practice data are limited. OBJECTIVE: This study examined the prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Puenpatom, Amy, Hull, Michael, McPheeters, Jeffrey, Schwebke, Kay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488145/
https://www.ncbi.nlm.nih.gov/pubmed/28386819
http://dx.doi.org/10.1007/s40261-017-0526-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488145/
https://www.ncbi.nlm.nih.gov/pubmed/28386819
http://dx.doi.org/10.1007/s40261-017-0526-z

Ejemplares similares